Home

Subscription

February 2017 issue

January 2017 issue



BACK ISSUES

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006


2012 Issues

December 2012 Issue
• A Christmas Letter
• New Drug Review: Mirabegron (Myrbetriq)
• Index for 2012


November 2012 Issue
• Feature - Pharmacy-Assisted Suicide - at CVS, Rite Aid, Walgreens, Walmart, etc.
• New Drug Review: Tofacitinib citrate (Xeljanz)


October 2012 Issue
• Feature - The Meningitis Tragedy - More Regulation is Not the Answer
• New Drug Review: Elvitegravir/Cobicistat (Stribild)


September 2012 Issue
• Feature - Our Professional Autonomy and the Health of our Patients are at Risk! We Need More Independence in our Practice Responsibilities and More Independent Pharmacies
• New Drug Review: Peginesatide acetate (Omontys)


August 2012 Issue
• Feature - Accreditation of Community Pharmacies Can Have Important Benefits - But the Program Must Have Credibility and Value for the Participants
• New Drug Review: Spinosad (Natroba)


July 2012 Issue
• Feature - The Restrictive and Risky Mail-order Distribution Program for Qsymia Must be Rescinded
• New Drug Review: Ezogabine (Potiga)


June 2012 Issue
• Feature - Is Patient Safety at Risk at CVS? There is a Whistleblower!
• New Drug Review: Aflibercept (Eylea)


May 2012 Issue
• Feature - The "Tyranny of the Urgent" Must Not Compromise our Commitment to our Priorities
• New Drug Review: Ingenol mebutate (Picato)


April 2012 Issue
• Feature - We Must Prevent "Reform" from Taking the "Care" out of Health Care!
• New Drug Review: Indacaterol maleate (Arcapta)


March 2012 Issue
• Feature - Many Prescription Medications Should be Available Without a Prescription from a Pharmacist
• New Drug Review: Fidaxomicin (Dificid)


February 2012 Issue
• Feature - CVS - Criminal Charges are Needed!
• New Drug Review: Roflumilast (Daliresp)


January 2012 Issue
• Feature - Pharmacy Must Establish its Own Prescription Benefit Program
• New Drug Review: Belimumab (Benlysta)